CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Medy Tox Inc (Parent) is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Medy Tox Inc (Parent)
78
Gangni 1-gil, Ochang-eup, Cheongwon-gu
Phone: +82 432171555p:+82 432171555 CHEONGJU, 28126  South Korea Fax: +82 432171557f:+82 432171557
Business Summary
Medy Tox Inc is a Korea-based company engaged in the development, manufacture and marketing of biopharmaceuticals. The Company’s main product is type A botulium toxin biopharmaceuticals which are used as remedies for blepharospasms, hemifacial spasms, eye wrinkles, hyperhidrosis diseases and infantile cerebral palsy. Its products are also used in chin plastic surgeries. The Company provides its products under the brand names of Medytoxin, Neurox, Siax, and Neuramis. In addition, the Company develops and sells medical devices such as injectors under the brand names of Neurajet, Neurafen and others. The Company also engages in technology transfer. The Company distributes its products in domestic and overseas markets such as Japan, China, Russia and Europe.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202112/31/2021Yes----

Industries
SIC Code Description
2836 Biological products, except diagnostic substances
3845 Electromedical and electrotherapeutic apparatus

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chief Executive Officer, Director Hyeon HoJung 60
Vice President, Director Hui SeokJoo 57 6/30/2021 1/1/2019
Vice President Du SikLee 60 1/1/2021 1/1/2021
6 additional Officers and Directors records available in full report.

General Information
Number of Employees: 122 (As of 12/31/2012)
Outstanding Shares: 6,658,228 (As of 6/30/2023)
Shareholders: 4,353
Stock Exchange: KDQ
Fax Number: +82 432171557


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, September 27, 2023